Vertex Pharmaceuticals VRTX Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.5B+8.2% | $5.09B+2.8% | $4.95B-0.7% | $4.98B+6.3% | $4.69B+2.5% | ||
| $1.75B+15.1% | $1.52B+13.1% | $1.35B-4.5% | $1.41B-7.6% | $1.53B-1.3% | ||
| $2B-2.8% | $2.05B+5.5% | $1.95B+2.8% | $1.89B+4.9% | $1.81B+12.2% | ||
| $1.77B+4.7% | $1.69B+3.7% | $1.63B+8.5% | $1.5B+10.3% | $1.36B+12.8% | ||
| $11.73B+4.7% | $11.2B+6.0% | $10.57B+1.4% | $10.43B+4.2% | $10.01B+4.3% | ||
| $1.09B0.0% | $1.09B0.0% | $1.09B0.0% | $1.09B0.0% | $1.09B0.0% | ||
| $26.48B+3.3% | $25.64B+3.1% | $24.86B+3.4% | $24.04B+5.1% | $22.88B+1.5% | ||
| $489.3M+6.0% | $461.7M+9.9% | $420.3M-5.0% | $442.3M-0.6% | $445M+7.7% | ||
| $3.88B+0.5% | $3.86B-13.7% | $4.48B+8.1% | $4.14B+9.4% | $3.78B+6.1% | ||
| $7.12B+2.1% | $6.98B-7.5% | $7.54B+9.9% | $6.86B+7.5% | $6.38B+4.3% | ||
| $14.59B+7.6% | $13.56B+9.6% | $12.37B+9.6% | $11.29B+10.1% | $10.25B+6.7% | ||
| $19.36B+3.7% | $18.67B+7.8% | $17.32B+0.8% | $17.18B+4.1% | $16.5B+0.5% | ||
| $26.48B+3.3% | $25.64B+3.1% | $24.86B+3.4% | $24.04B+5.1% | $22.88B+1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Vertex Pharmaceuticals's total assets?
- Vertex Pharmaceuticals (VRTX) holds $26.5B in total assets, up 15.8% year over year.
- How much debt does Vertex Pharmaceuticals have?
- Vertex Pharmaceuticals carries $2.0B in total debt against $19.4B of shareholders' equity, a debt-to-equity ratio of 0.10.
- How much cash does Vertex Pharmaceuticals have?
- Vertex Pharmaceuticals holds $5.5B in cash and equivalents.
- Can Vertex Pharmaceuticals cover its short-term obligations?
- Its current ratio is 3.02 — current assets exceed current liabilities.
- Where does Vertex Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Vertex Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
